SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Decrease in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 58,800 shares, a decline of 26.3% from the October 15th total of 79,800 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average daily trading volume, of 64,100 shares, the days-to-cover ratio is presently 0.9 days.

Analyst Upgrades and Downgrades

SABS has been the topic of several recent analyst reports. Oppenheimer reissued an “outperform” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Craig Hallum started coverage on shares of SAB Biotherapeutics in a research report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a research report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, SAB Biotherapeutics has an average rating of “Buy” and an average price target of $12.40.

Institutional Investors Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC acquired a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned approximately 0.21% of SAB Biotherapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Down 16.2 %

SABS traded down $0.60 on Friday, reaching $3.10. 84,880 shares of the company traded hands, compared to its average volume of 30,583. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a one year low of $2.16 and a one year high of $9.72. The firm has a fifty day simple moving average of $2.95 and a two-hundred day simple moving average of $2.98.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Sell-side analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.